ReviewCurrent drug targets2026
Possible Applications of Azurin, a Copper-Containing Protein, in Cancer Treatment: Prospects and Challenges.
Review in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionConventional cancer therapies are limited by systemic toxicity, poor selectivity, and drug resistance. Bacterial proteins, such as azurin, represent a promising alternative due to their tumor selectivity, low immunogenicity, and multifunctional mechanisms. This review highlights recent progress in azurin-based anticancer strategies, including mechanisms of action, structural modifications, and integration with peptide systems, nanotechnology, and gene therapy.
methodsA search for articles using the keywords "azurin, cancer" was conducted on the Google Scholar and PubMed databases, with an emphasis on the years 2023-2024.
resultsAzurin and its peptide derivative p28 selectively target cancer cells by stabilizing p53, inducing apoptosis, and arresting the cell cycle, while also modulating key signaling pathways. Structural features of azurin enable interactions with multiple molecular targets, and p28 enhances cellular uptake and sensitizes tumors to chemotherapeutics. Advanced delivery platforms, including engineered bacteria (E. coli Nissle 1917, S. typhimurium VNP-20009), chimeric peptides, and nanocarriers, improve tumor targeting and therapeutic outcomes. Preclinical models and clinical trials demonstrate low toxicity and efficacy against various solid tumors and gliomas. DISCUSSION: Evidence supports azurin as a versatile anticancer agent with unique advantages over conventional therapies. Its compatibility with delivery innovations enhances precision and minimizes systemic toxicity. However, further optimization, large-scale clinical validation, and long-term safety studies are required.
conclusionAzurin and its derivatives provide a promising platform for anticancer therapy, offering tumor specificity, low toxicity, and synergy with multiple treatment modalities. Their integration into advanced delivery and genetic systems may significantly improve cancer treatment and recurrence prevention.
Indexed as
Identifiers
41588952What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.